+关注
enyj
暂无个人介绍
IP属地：未知
8
关注
0
粉丝
0
主题
0
勋章
主贴
热门
enyj
2021-06-16
concern
抱歉，原内容已删除
enyj
2021-06-16
cool
抱歉，原内容已删除
enyj
2021-06-16
Interesting read!
抱歉，原内容已删除
enyj
2021-06-16
geo
Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally
去老虎APP查看更多动态
{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3586783123137653","uuid":"3586783123137653","gmtCreate":1623689098667,"gmtModify":1623689098667,"name":"enyj","pinyin":"enyj","introduction":"","introductionEn":"","signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":8,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.02.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":169567461,"gmtCreate":1623843826453,"gmtModify":1634027245219,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586783123137653","authorIdStr":"3586783123137653"},"themes":[],"htmlText":"concern","listText":"concern","text":"concern","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169567461","repostId":"2143530687","repostType":4,"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169564402,"gmtCreate":1623843796506,"gmtModify":1634027246110,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586783123137653","authorIdStr":"3586783123137653"},"themes":[],"htmlText":"cool","listText":"cool","text":"cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169564402","repostId":"1117953789","repostType":4,"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169598006,"gmtCreate":1623841526005,"gmtModify":1634027279819,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586783123137653","authorIdStr":"3586783123137653"},"themes":[],"htmlText":"Interesting read!","listText":"Interesting read!","text":"Interesting read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169598006","repostId":"2143476097","repostType":4,"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169593843,"gmtCreate":1623841457482,"gmtModify":1634027281196,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3586783123137653","authorIdStr":"3586783123137653"},"themes":[],"htmlText":"geo","listText":"geo","text":"geo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169593843","repostId":"1150256789","repostType":4,"repost":{"id":"1150256789","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8 <a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":169567461,"gmtCreate":1623843826453,"gmtModify":1634027245219,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586783123137653","idStr":"3586783123137653"},"themes":[],"htmlText":"concern","listText":"concern","text":"concern","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169567461","repostId":"2143530687","repostType":4,"repost":{"id":"2143530687","pubTimestamp":1623829500,"share":"https://www.laohu8.com/m/news/2143530687?lang=&edition=full","pubTime":"2021-06-16 15:45","market":"us","language":"en","title":"How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?","url":"https://stock-news.laohu8.com/highlight/detail?id=2143530687","media":"Motley Fool","summary":"It's way too early to worry.","content":"<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by <b>Pfizer</b> (NYSE:PFE) and <b>BioNTech</b> (NASDAQ:BNTX). More than 129 million Americans have received <b>Moderna</b>'s (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.</p> \n<p>However, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?</p> \n<h2>Behind the concerns</h2> \n<p>The CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.</p> \n<p>However, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.</p> \n<p>As of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.</p> \n<p>The potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.</p> \n<h2>Reason to worry?</h2> \n<p>The CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"</p> \n<p>The number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"</p> \n<p>It's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"</p> \n<p>Based on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.</p> \n<p>That could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.</p> \n<h2>Minimal movement</h2> \n<p>Should investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.</p> \n<p>Granted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.</p> \n<p>The emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Worrisome Are Heart Issues Reported With Pfizer's and Moderna's COVID Vaccines?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:45 GMT+8 <a href=https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE","PFE":"辉瑞"},"source_url":"https://www.fool.com/investing/2021/06/15/how-worrisome-are-heart-issues-reported-with-pfize/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143530687","content_text":"Nearly 170 million Americans have received the COVID-19 vaccine developed by Pfizer (NYSE:PFE) and BioNTech (NASDAQ:BNTX). More than 129 million Americans have received Moderna's (NASDAQ:MRNA) vaccine. So far, the vaccines have appeared to be both highly effective and safe.\nHowever, the Centers for Disease Control and Prevention (CDC) is convening an \"emergency meeting\" of an advisory panel on June 18. The panel will discuss higher-than-expected reports of heart inflammation issues in young men following the second dose of the two messenger RNA (mRNA) COVID-19 vaccines. How worrisome are these heart issues reported with Pfizer's and Moderna's COVID-19 vaccines?\nBehind the concerns\nThe CDC and the U.S. Food and Drug Administration (FDA) jointly run the Vaccine Adverse Event Reporting System (VAERS), which tracks reports of any side effects after individuals have received a COVID-19 vaccine. Most adverse events reported in VAERS aren't serious.\nHowever, the CDC noticed that higher numbers of myocarditis (inflammation of the middle layer of the heart wall) and pericarditis (inflammation of the pericardium tissue that surrounds the heart) were being reported for young men than would be expected based on the number of vaccines administered. These issues were especially notable after the second dose of the mRNA vaccines.\nAs of May 31, 372 cases of myocarditis or pericarditis had been reported in VAERS after the second dose of the Pfizer-BioNTech vaccine. Another 201 cases of heart inflammation issues had been reported after the second dose of Moderna's vaccine. Nearly 80% of these reported cases occurred in men, with a median age of 24.\nThe potential issues aren't limited to the United States. Earlier this month, Israel's Health Ministry announced that there was a \"probable link\" between heart inflammation issues observed primarily in young men and receiving the second dose of the Pfizer-BioNTech vaccine.\nReason to worry?\nThe CDC hasn't established any causal link between either of the mRNA vaccines and heart inflammation issues occurring in young men at this point. Moderna issued a public statement last week that confirmed it hasn't found any causal association between its vaccine and heart inflammation \"after carefully reviewing the safety data to date.\"\nThe number of heart inflammation issues reported thus far, while higher than expected, is still really low overall. The CDC specifically stated that \"these reports are rare, given the number of vaccine doses administered.\"\nIt's also important to note that most individuals affected by heart inflammation issues were treated successfully. Indeed, the CDC said, \"Most patients who received care responded well to medicine and rest and quickly felt better.\"\nBased on what is known now, there's no reason for individuals receiving the Pfizer-BioNTech or Moderna COVID-19 vaccines to worry. Finding rare side effects with a vaccine or a drug is launched occurs frequently. Usually, the actions taken include revising guidelines for evaluating the benefit-risk balance for affected groups and the follow-up monitoring for these groups.\nThat could be what the CDC advisory panel that's scheduled to meet later this week will do after examining the available data. It's also possible that the panel will need more data before it makes any recommendations.\nMinimal movement\nShould investors worry about what all of this might mean for Pfizer, BioNTech, and/or Moderna? No. Most investors haven't been worried, as evidenced by the minimal movement of the drug stocks after the initial CDC advisory committee meeting last week where the heart inflammation issues were discussed.\nGranted, it's possible that a clear link between the mRNA vaccines and heart inflammation issues in young men could be established. Even if that happens, though, the issues are rare enough that the number of doses administered of these vaccines probably wouldn't be impacted very much.\nThe emergence of new coronavirus strains makes it far more likely that more mRNA vaccine doses will be needed in the future. In the big scheme of things, Pfizer's and Moderna's COVID-19 vaccines are providing a lot more reasons for celebration than for concern.","news_type":1},"isVote":1,"tweetType":1,"viewCount":250,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169564402,"gmtCreate":1623843796506,"gmtModify":1634027246110,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586783123137653","idStr":"3586783123137653"},"themes":[],"htmlText":"cool","listText":"cool","text":"cool","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169564402","repostId":"1117953789","repostType":4,"repost":{"id":"1117953789","pubTimestamp":1623829736,"share":"https://www.laohu8.com/m/news/1117953789?lang=&edition=full","pubTime":"2021-06-16 15:48","market":"us","language":"en","title":"First Look: Solid Power, a Ford-Backed QuantumScape Rival, Will Go Public via SPAC","url":"https://stock-news.laohu8.com/highlight/detail?id=1117953789","media":"fool","summary":"Solid Power, a promising solid-state battery start-up backed by Ford Motor(NYSE:F)and BMW, said that","content":"<p>Solid Power, a promising solid-state battery start-up backed by <b>Ford Motor</b>(NYSE:F)and <b>BMW</b>, said that it has agreed to go public via a merger with special purpose acquisition company (SPAC)<b>Decarbonization Plus Acquisition III</b>(NASDAQ:DCRC).</p>\n<p>The deal values the combined company at about $1.2 billion.</p>\n<p>Many investors have been overwhelmed by the number of SPAC deals in the electric-vehicle space over the last year, and some have soured on the space now that a couple of last year's darlings have turned out to be, well, less than they seemed.But if you still believe that electric vehicles are the future (I do), Solid Power is worth a close look. It's a company with real potential, with some big customers ready and waiting for its products, and with technology that's much closer to mass production than that of its most prominent rivals.</p>\n<p><b>What is Solid Power</b></p>\n<p>Colorado-based Solid Power, founded in 2012, is one of several companies working to develop so-called solid-state batteries, which omit the liquid electrolyte used in the lithium-ion batteries that power most electric vehicles today. (Among the others:<b>QuantumScape</b>(NYSE:QS), which drew lots of attention from investors after it went public via its own SPAC deal late last year.)</p>\n<p>Solid-state batteries have the potential to offer greater energy density than lithium-ion batteries with less weight, but a design that can be mass-produced at a reasonable cost has eluded researchers for years.</p>\n<p>That may soon change.</p>\n<p><b>What makes this a big deal</b></p>\n<p>First and foremost, Solid Power appears to be closer to mass production than its rivals. Most solid-state battery efforts are at least a few years away from production. QuantumScape, for example, is<i>hoping</i>tobegin pilot production of its batteriesin about three years. But Solid Power is already producing its second-generation 20 ampere-hour (Ah) battery cells on a pilot production line, and it expects to begin pilot production of its full-scale 100 Ah batteries next year.</p>\n<p>Second -- again, unlike most competitors -- Solid Power's solid-state battery cells can be manufactured with equipment and processes adapted from lithium-ion battery manufacturing, meaning that existing battery plants can be converted to build Solid Power's cells at relatively low cost.</p>\n<p>Finally, as I mentioned above, bothFord and BMW are investors in Solid Power. Both participated in the company's most recent funding round earlier this year, both expect to receive batches of those 100 Ah cells for testing in their own electric vehicles next year, and assuming those tests go well, both will be early customers for the company's mass-produced cells.</p>\n<p><b>What are the terms of the Solid Power SPAC deal</b></p>\n<p>Solid Power's deal to merge with Decarbonization Plus III follows the pattern of other SPAC deals we've seen in the electric vehicle space over the past year, in that it includes a PIPE (for \"private investment in public equity\") that allows big investors to buy stock in the merged company at an agreed-upon price, adding extra cash to the deal.</p>\n<p>Here are the key points of the deal:</p>\n<ul>\n <li>Decarbonization Plus III is contributing the cash it holds in trust, about $350 million.</li>\n <li>The PIPE will bring another $165 million from investors including<b>Riverstone Energy</b>, Koch Industries' venture-capital fund, and funds advised by Neuberger Berman and VanEck Global.</li>\n <li>Together with the $135 million that Solid Power raised in its Series B round last month, the post-merger company will have about $650 million in cash.</li>\n <li>The merged company will retain the Solid Power name and will trade on the Nasdaq Stock Market under the ticker symbol \"SLDP.\"</li>\n <li>The deal is expected to close in the fourth quarter of 2021.</li>\n</ul>\n<p><b>What are the risks if I buy DCRC now</b></p>\n<p>As with any SPAC deal involving a company that hasn't yet brought its product to market, there are risks investors should keep in mind:</p>\n<ul>\n <li>It's possible that the deal won't close, or that it'll close later than scheduled.</li>\n <li>It's possible that the company's technology won't pan out, or that it goes into production later than expected. Investors who are used to tech start-up time frames should note that the pace of progress in the battery space is<i>glacial</i>by comparison. Solid Power has been working on its batteries since 2012, QuantumScape since 2010.</li>\n <li>It's possible that one or more competitors will beat Solid Power to market, taking significant share.</li>\n <li>It's possible that we'll learn things about Solid Power that make it a less attractive investment. (I have no reason to think this will happen, but all SPAC investors should be mindful of the examples of<b>Nikola</b>and<b>Lordstown Motors</b>, both of which made important claims that werelater foundtohave been exaggerated.)</li>\n</ul>\n<p><b>Is DCRC a buy</b></p>\n<p>I'm not sure yet, but right now I'm leaning toward \"yes.\" Solid Power's technology is very promising, and executives at Ford think highly of the company's technology and leadership team. As with any battery start-up, the question is when (and whether) the company can bring its batteries to market -- but I think Solid Power will still have good growth potential even if production slips by a year or two.</p>\n<p>That said, I'm still working through all of the company's investor materials, and I expect to have more thoughts on Solid Power's valuation and growth potential in a few days. Stay tuned.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First Look: Solid Power, a Ford-Backed QuantumScape Rival, Will Go Public via SPAC</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst Look: Solid Power, a Ford-Backed QuantumScape Rival, Will Go Public via SPAC\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 15:48 GMT+8 <a href=https://www.fool.com/investing/2021/06/15/first-look-solid-power-a-ford-backed-quantumscape/><strong>fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Solid Power, a promising solid-state battery start-up backed by Ford Motor(NYSE:F)and BMW, said that it has agreed to go public via a merger with special purpose acquisition company (SPAC)...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/15/first-look-solid-power-a-ford-backed-quantumscape/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/06/15/first-look-solid-power-a-ford-backed-quantumscape/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1117953789","content_text":"Solid Power, a promising solid-state battery start-up backed by Ford Motor(NYSE:F)and BMW, said that it has agreed to go public via a merger with special purpose acquisition company (SPAC)Decarbonization Plus Acquisition III(NASDAQ:DCRC).\nThe deal values the combined company at about $1.2 billion.\nMany investors have been overwhelmed by the number of SPAC deals in the electric-vehicle space over the last year, and some have soured on the space now that a couple of last year's darlings have turned out to be, well, less than they seemed.But if you still believe that electric vehicles are the future (I do), Solid Power is worth a close look. It's a company with real potential, with some big customers ready and waiting for its products, and with technology that's much closer to mass production than that of its most prominent rivals.\nWhat is Solid Power\nColorado-based Solid Power, founded in 2012, is one of several companies working to develop so-called solid-state batteries, which omit the liquid electrolyte used in the lithium-ion batteries that power most electric vehicles today. (Among the others:QuantumScape(NYSE:QS), which drew lots of attention from investors after it went public via its own SPAC deal late last year.)\nSolid-state batteries have the potential to offer greater energy density than lithium-ion batteries with less weight, but a design that can be mass-produced at a reasonable cost has eluded researchers for years.\nThat may soon change.\nWhat makes this a big deal\nFirst and foremost, Solid Power appears to be closer to mass production than its rivals. Most solid-state battery efforts are at least a few years away from production. QuantumScape, for example, ishopingtobegin pilot production of its batteriesin about three years. But Solid Power is already producing its second-generation 20 ampere-hour (Ah) battery cells on a pilot production line, and it expects to begin pilot production of its full-scale 100 Ah batteries next year.\nSecond -- again, unlike most competitors -- Solid Power's solid-state battery cells can be manufactured with equipment and processes adapted from lithium-ion battery manufacturing, meaning that existing battery plants can be converted to build Solid Power's cells at relatively low cost.\nFinally, as I mentioned above, bothFord and BMW are investors in Solid Power. Both participated in the company's most recent funding round earlier this year, both expect to receive batches of those 100 Ah cells for testing in their own electric vehicles next year, and assuming those tests go well, both will be early customers for the company's mass-produced cells.\nWhat are the terms of the Solid Power SPAC deal\nSolid Power's deal to merge with Decarbonization Plus III follows the pattern of other SPAC deals we've seen in the electric vehicle space over the past year, in that it includes a PIPE (for \"private investment in public equity\") that allows big investors to buy stock in the merged company at an agreed-upon price, adding extra cash to the deal.\nHere are the key points of the deal:\n\nDecarbonization Plus III is contributing the cash it holds in trust, about $350 million.\nThe PIPE will bring another $165 million from investors includingRiverstone Energy, Koch Industries' venture-capital fund, and funds advised by Neuberger Berman and VanEck Global.\nTogether with the $135 million that Solid Power raised in its Series B round last month, the post-merger company will have about $650 million in cash.\nThe merged company will retain the Solid Power name and will trade on the Nasdaq Stock Market under the ticker symbol \"SLDP.\"\nThe deal is expected to close in the fourth quarter of 2021.\n\nWhat are the risks if I buy DCRC now\nAs with any SPAC deal involving a company that hasn't yet brought its product to market, there are risks investors should keep in mind:\n\nIt's possible that the deal won't close, or that it'll close later than scheduled.\nIt's possible that the company's technology won't pan out, or that it goes into production later than expected. Investors who are used to tech start-up time frames should note that the pace of progress in the battery space isglacialby comparison. Solid Power has been working on its batteries since 2012, QuantumScape since 2010.\nIt's possible that one or more competitors will beat Solid Power to market, taking significant share.\nIt's possible that we'll learn things about Solid Power that make it a less attractive investment. (I have no reason to think this will happen, but all SPAC investors should be mindful of the examples ofNikolaandLordstown Motors, both of which made important claims that werelater foundtohave been exaggerated.)\n\nIs DCRC a buy\nI'm not sure yet, but right now I'm leaning toward \"yes.\" Solid Power's technology is very promising, and executives at Ford think highly of the company's technology and leadership team. As with any battery start-up, the question is when (and whether) the company can bring its batteries to market -- but I think Solid Power will still have good growth potential even if production slips by a year or two.\nThat said, I'm still working through all of the company's investor materials, and I expect to have more thoughts on Solid Power's valuation and growth potential in a few days. Stay tuned.","news_type":1},"isVote":1,"tweetType":1,"viewCount":95,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169598006,"gmtCreate":1623841526005,"gmtModify":1634027279819,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586783123137653","idStr":"3586783123137653"},"themes":[],"htmlText":"Interesting read!","listText":"Interesting read!","text":"Interesting read!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169598006","repostId":"2143476097","repostType":4,"repost":{"id":"2143476097","weMediaInfo":{"introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"media_name":"Dow Jones","id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"pubTimestamp":1623832320,"share":"https://www.laohu8.com/m/news/2143476097?lang=&edition=full","pubTime":"2021-06-16 16:32","market":"hk","language":"en","title":"Investors press pause with stocks largely steady as Federal Reserve decision looms","url":"https://stock-news.laohu8.com/highlight/detail?id=2143476097","media":"Dow Jones","summary":"Miners fall as China aims to cool soaring commodity prices. European stocks inched up on Wednesday, while U.S. equity futures traded flat as investors waited for the outcome of a Federal Reserve policy meeting due later. Miners were lower as China took aim at soaring commodity prices.The Stoxx Europe 600 index rose 0.1% , the German DAX was down 0.3%, the French CAC 40 was up 0.1% and the FTSE 100 index was up 0.1%.U.S. equity futures held steady a day after the S&P 500 and Nasdaq Composite back","content":"<p>Miners fall as China aims to cool soaring commodity prices</p>\n<p>European stocks inched up on Wednesday, while U.S. equity futures traded flat as investors waited for the outcome of a Federal Reserve policy meeting due later. Miners were lower as China took aim at soaring commodity prices.</p>\n<p>The Stoxx Europe 600 index rose 0.1% , the German DAX was down 0.3%, the French CAC 40 was up 0.1% and the FTSE 100 index was up 0.1%.</p>\n<p>U.S. equity futures held steady a day after the S&P 500 and Nasdaq Composite backed away from records to close lower on Tuesday, with the Dow Jones Industrial Average also dropping. Stocks slipped following data that showed a bigger-than-expected drop in May retail sales, while producer prices rose faster than expected.</p>\n<p>The outcome of the two-day Federal Open Market Committee meeting and a news conference with Chairman Jerome Powell will come after the close of European markets. The central bank is largely expected to keep its ultra-supportive policy unchanged and continue its bond-buying program even amid surging inflation.</p>\n<p>Read:4 things to watch for when the Fed meets Wednesday</p>\n<p>\"At some point, there will need to be a signal that the currently easy monetary conditions will be scaled back. The expectation is that the subject of tapering some of the relief has at least made its way to the table for discussion, if not immediate action,\" said Richard Hunter, head of markets at interactive investor, in a note to clients.</p>\n<p>Elsewhere, U.K. consumer prices rose 2.1% on the year in May, the fastest pace of growth since July 2019, the Office for National Statistics said on Wednesday. The rise exceeded the Bank of England's target for the first time in almost two years. But like the Fed and other central banks, U.K. officials have said they expect price rises to be transitory.</p>\n<p>Economic data from China showed a moderating of growth in May , with industrial production, while retail sales and fixed-asset investment all rising, but slowing from the pace seen in year-earlier periods.</p>\n<p>Mining stocks fell after China's state stockpiling body said Wednesday that it will release national metals reserves such as copper and aluminum batches in the near future to keep supply and prices stable. Commodity prices have been soaring around the world as some economies speed up recoveries from the pandemic.</p>\n<p>Read:Commodities are now the most crowded trade, say global fund managers</p>\n<p>Shares of Anglo American fell 1.8% and Glencore nearly 2%. Rio Tinto (RIO.LN) shares slipped 0.5%. Copper and palladium prices shifted lower on Wednesday.</p>\n<p>Shares of German business software group fell SAP (SAP.XE) fell on the heels of results from U.S. rival Oracle <a href=\"https://laohu8.com/S/ORCL\">$(ORCL)$</a>, which soundly beat expectations for earnings and sales to close out its fiscal year on Tuesday. However, Oracle shares slipped amid softer-than-anticipated guidance for the August quarter.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Investors press pause with stocks largely steady as Federal Reserve decision looms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInvestors press pause with stocks largely steady as Federal Reserve decision looms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2021-06-16 16:32</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>Miners fall as China aims to cool soaring commodity prices</p>\n<p>European stocks inched up on Wednesday, while U.S. equity futures traded flat as investors waited for the outcome of a Federal Reserve policy meeting due later. Miners were lower as China took aim at soaring commodity prices.</p>\n<p>The Stoxx Europe 600 index rose 0.1% , the German DAX was down 0.3%, the French CAC 40 was up 0.1% and the FTSE 100 index was up 0.1%.</p>\n<p>U.S. equity futures held steady a day after the S&P 500 and Nasdaq Composite backed away from records to close lower on Tuesday, with the Dow Jones Industrial Average also dropping. Stocks slipped following data that showed a bigger-than-expected drop in May retail sales, while producer prices rose faster than expected.</p>\n<p>The outcome of the two-day Federal Open Market Committee meeting and a news conference with Chairman Jerome Powell will come after the close of European markets. The central bank is largely expected to keep its ultra-supportive policy unchanged and continue its bond-buying program even amid surging inflation.</p>\n<p>Read:4 things to watch for when the Fed meets Wednesday</p>\n<p>\"At some point, there will need to be a signal that the currently easy monetary conditions will be scaled back. The expectation is that the subject of tapering some of the relief has at least made its way to the table for discussion, if not immediate action,\" said Richard Hunter, head of markets at interactive investor, in a note to clients.</p>\n<p>Elsewhere, U.K. consumer prices rose 2.1% on the year in May, the fastest pace of growth since July 2019, the Office for National Statistics said on Wednesday. The rise exceeded the Bank of England's target for the first time in almost two years. But like the Fed and other central banks, U.K. officials have said they expect price rises to be transitory.</p>\n<p>Economic data from China showed a moderating of growth in May , with industrial production, while retail sales and fixed-asset investment all rising, but slowing from the pace seen in year-earlier periods.</p>\n<p>Mining stocks fell after China's state stockpiling body said Wednesday that it will release national metals reserves such as copper and aluminum batches in the near future to keep supply and prices stable. Commodity prices have been soaring around the world as some economies speed up recoveries from the pandemic.</p>\n<p>Read:Commodities are now the most crowded trade, say global fund managers</p>\n<p>Shares of Anglo American fell 1.8% and Glencore nearly 2%. Rio Tinto (RIO.LN) shares slipped 0.5%. Copper and palladium prices shifted lower on Wednesday.</p>\n<p>Shares of German business software group fell SAP (SAP.XE) fell on the heels of results from U.S. rival Oracle <a href=\"https://laohu8.com/S/ORCL\">$(ORCL)$</a>, which soundly beat expectations for earnings and sales to close out its fiscal year on Tuesday. However, Oracle shares slipped amid softer-than-anticipated guidance for the August quarter.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"RIO.AU":"力拓","RIO":"力拓","ISBC":"投资者银行"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2143476097","content_text":"Miners fall as China aims to cool soaring commodity prices\nEuropean stocks inched up on Wednesday, while U.S. equity futures traded flat as investors waited for the outcome of a Federal Reserve policy meeting due later. Miners were lower as China took aim at soaring commodity prices.\nThe Stoxx Europe 600 index rose 0.1% , the German DAX was down 0.3%, the French CAC 40 was up 0.1% and the FTSE 100 index was up 0.1%.\nU.S. equity futures held steady a day after the S&P 500 and Nasdaq Composite backed away from records to close lower on Tuesday, with the Dow Jones Industrial Average also dropping. Stocks slipped following data that showed a bigger-than-expected drop in May retail sales, while producer prices rose faster than expected.\nThe outcome of the two-day Federal Open Market Committee meeting and a news conference with Chairman Jerome Powell will come after the close of European markets. The central bank is largely expected to keep its ultra-supportive policy unchanged and continue its bond-buying program even amid surging inflation.\nRead:4 things to watch for when the Fed meets Wednesday\n\"At some point, there will need to be a signal that the currently easy monetary conditions will be scaled back. The expectation is that the subject of tapering some of the relief has at least made its way to the table for discussion, if not immediate action,\" said Richard Hunter, head of markets at interactive investor, in a note to clients.\nElsewhere, U.K. consumer prices rose 2.1% on the year in May, the fastest pace of growth since July 2019, the Office for National Statistics said on Wednesday. The rise exceeded the Bank of England's target for the first time in almost two years. But like the Fed and other central banks, U.K. officials have said they expect price rises to be transitory.\nEconomic data from China showed a moderating of growth in May , with industrial production, while retail sales and fixed-asset investment all rising, but slowing from the pace seen in year-earlier periods.\nMining stocks fell after China's state stockpiling body said Wednesday that it will release national metals reserves such as copper and aluminum batches in the near future to keep supply and prices stable. Commodity prices have been soaring around the world as some economies speed up recoveries from the pandemic.\nRead:Commodities are now the most crowded trade, say global fund managers\nShares of Anglo American fell 1.8% and Glencore nearly 2%. Rio Tinto (RIO.LN) shares slipped 0.5%. Copper and palladium prices shifted lower on Wednesday.\nShares of German business software group fell SAP (SAP.XE) fell on the heels of results from U.S. rival Oracle $(ORCL)$, which soundly beat expectations for earnings and sales to close out its fiscal year on Tuesday. However, Oracle shares slipped amid softer-than-anticipated guidance for the August quarter.","news_type":1},"isVote":1,"tweetType":1,"viewCount":185,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":169593843,"gmtCreate":1623841457482,"gmtModify":1634027281196,"author":{"id":"3586783123137653","authorId":"3586783123137653","name":"enyj","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3586783123137653","idStr":"3586783123137653"},"themes":[],"htmlText":"geo","listText":"geo","text":"geo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/169593843","repostId":"1150256789","repostType":4,"repost":{"id":"1150256789","pubTimestamp":1623833619,"share":"https://www.laohu8.com/m/news/1150256789?lang=&edition=full","pubTime":"2021-06-16 16:53","market":"us","language":"en","title":"Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally","url":"https://stock-news.laohu8.com/highlight/detail?id=1150256789","media":"benzinga","summary":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the","content":"<p><b>Orphazyme A/S’s</b> major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.</p>\n<p><b>What Happened</b>: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.</p>\n<p>In March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.</p>\n<p>Only two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.</p>\n<p><b>Why It Matters</b>: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.</p>\n<p>In a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.</p>\n<p>However, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.</p>\n<p><b>Price Action</b>: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.</p>","source":"lsy1606299360108","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme Major Investor Sunstone Cut Stake After Retail Investor-Driven Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-16 16:53 GMT+8 <a href=https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally><strong>benzinga</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened...</p>\n\n<a href=\"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.benzinga.com/news/21/06/21582310/orphazyme-major-investor-sunstone-cut-stake-after-retail-investor-driven-rally","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150256789","content_text":"Orphazyme A/S’s major shareholder Sunstone Life Science Ventures has reduced its stake following the retail investor-driven rally in the Denmark-based biopharmaceutical company’s shares.\nWhat Happened: Orphazyme said on Tuesday it received a notice from Copenhagen-based Sunstone Life Science Ventures that as of June 11, funds held by Sunstone hold less than 5% of the company’s share capital.\nIn March, Orphazyme had disclosed in its annual report that Sunstone owned 5.2% of the company’s shares, according to areportby Bloomberg.\nOnly two investors — LSP V Coöperatieve U.A. with a 7.81% stake and Coöperative Aescap Venture I U.A. with a 5.1% stake — now own more than 5% of Orphazyme’s shares, the report added.\nWhy It Matters: Last week, Orphazyme emergedas one of the so-called stonks, or stocks popular with retail investors. The company’s sharesskyrocketedalmost 1,400% at one point on Thursday.\nIn a regulatory filing, Orphazyme said it isn't aware of any material change in its clinical development programs, financial condition or results of operations that would explain the price volatility in its shares that occurred since last Thursday.\nHowever, the FDA is scheduled to rule on Orphazyme's NDA for Arimocolmol for the treatment of Niemann-Pick Disease Type C, on Thursday, June 17.\nPrice Action: Orphazyme shares closed 9.5% lower in Tuesday’s trading at $10.05.","news_type":1},"isVote":1,"tweetType":1,"viewCount":169,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
